Figure 1 Relapse and rituximab historyThe figure shows rituximab (RTX) treatment history as well as relapse history for 100 days prior to the first RTX.

Slides:

Advertisements

Similar presentations

Devic’s neuromyelitis optica: its distinctive features and treatment

Advertisements

“My migraine always comes back” Presented by: Julio Pascual Neuroscience Area, Service of Neurology, University Hospital Central de Asturias and Ineuropa,

Teaching NeuroImages Neurology Resident and Fellow Section © 2013 American Academy of Neurology A 51-year-old woman with triplegia and blindness.

V V TRIGEMINAL NEURALGIA MAY HERALD NEUROMYELITIS OPTICA SPECTRUM DISORDERS Gisele O. Lima, Natália C. Talim, Lívia E. C. Talim, Juliana M. S. S. Amaral,

Int J MS Care 7: , 2005/2006. Jan 9 & 10, Clinical Stabilization of a MS Patient after Tonsillectomy presented by Michael C. Levin, MD Department.

Date of download: 6/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Short Myelitis Lesions in Aquaporin-4-IgG–Positive.

Carrie M. Hersh, D.O., Robert Fox, M.D.

A 26-y.o. woman with RRMS and eruption of plaques.

Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

A 22 year old woman with progressive vision loss

Figure 2. Infliximab treatment effect

Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.

Figure MRI of anti-MOG-IgG–associated myelitis

Figure 2 Orbital MRI findings One-third of myelin oligodendrocyte glycoprotein antibody–positive patients revealed extensive enhancement patterns that.

Figure 1 Percent positivity by clinical feature Overall, 6

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure 2 Temporal distribution of MOG antibody in serum of 2 relapsing patients with demyelinating diseases Temporal distribution of MOG antibody in serum.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Patient flow diagram

Figure 3 Example of venous narrowing

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Figure 2 NMDAR-Ab levels, clinical syndromes, and therapy in 8 informative patients with white matter syndromes in association with NMDAR-Ab NMDAR-Ab levels,

Figure 1 ERG peak time delay at baseline

Figure 3. MRI of compressive optic neuropathy caused by dural lesions in sarcoidosis MRI of compressive optic neuropathy caused by dural lesions in sarcoidosis.

Figure 2 Clinical course and response to therapy in 6 Australian patients with HMGCR antibodies The clinical course, creatine kinase (CK) levels, Medical.

Figure 1 Cerebral MRI during the disease course Cerebral MRI with multiple cerebral supratentorial lesions during the disease course: periventricular lesions.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 3 EEG demonstrating ictal seizure discharges in a patient with faciobrachial dystonic seizures The EEG of a 56-year-old woman with faciobrachial.

Figure 1 Characteristics of the German National MS Cohort

Figure 1 Time points of blood sampling

Figure 2 Concordance of results for commercial cell-based assay (CBA) and fluorescence-activated cell sorting (FACS) assays, FACS titers, and disease activity.

Figure 2 Representative brain MRIs from patients with neuromyelitis optica Lesions are localized at sites of high aquaporin-4 expression (white dots).

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Figure 4 Pattern of relapse in patients with MOG-Ab Five myelin oligodendrocyte glycoprotein antibody (MOG-Ab)–positive patients experienced a relapse,

Figure 2 Cerebral and spinal MRI (A) Restricted diffusion of both optic nerves (arrows) on diffusion-weighted and apparent diffusion coefficient imaging.

Figure 1 JCV serostatus JCV serostatus (A) Serostatus of 1,921 natalizumab-treated patients with multiple sclerosis, with JCV− patients shown in black.

Figure 2 Proposed approach to treating myositis-associated interstitial lung disease Figure 2 | Proposed approach to treating myositis-associated interstitial.

Figure 2 Individual EDSS scores

Figure 4 Confirmatory cohorts to assess MOG-IgG1 assay(A) All 81 aquaporin-4 (AQP4)- seropositive patients (blue) from the Oxford National neuromyelitis.

Figure Clinical and radiologic course(A) The T2 contrast-enhanced sequence on day 3 shows an extensive central cord lesion extending from C2 to T7. Clinical.

Figure 1 Kaplan-Meier estimation of time to neuromyelitis optica (NMO) conversion and development of motor disability Kaplan-Meier estimation of time to.

Figure Time course of the patient's diagnostics and treatment

Figure 1. Antibodies to MOG in a proportion of adult patients with MS

Figure Postcontrast axial and coronal brain MRI in a patient with CLIPPERS treated with hydroxychloroquineT1-weighted spin echo post IV gadolinium contrast.

MS Relapse Management: Team Approaches Colleen Harris MN NP MSCN

Figure 2 Clinical and autoantibody status of 2 CNTN1 or NF155+ patients not receiving rituximab Despite corticosteroids and methotrexate treatment, patient.

Figure Overview of patients with demyelinating diseases, presence of clinical symptoms frequently associated with NMDAR encephalitis, and antibody status.

Figure 1 Radiologic features of patients with white matter syndromes in association with NMDA receptor antibodies Radiologic features of patients with.

Figure 2 Summary of the utility of MOG-Abs and OCB testing in predicting pediatric disease course at onset compared to clinical follow-up at 1 yearFollowing.

Figure 1 Clinical status and autoantibody titers in rituximab-treated patients with anti-CNTN1/NF155 chronic inflammatory demyelinating polyneuropathy.

Figure 2 Pre- and posttreatment contrast-enhanced MRI of second toxoplasmosis lesion in case 1(A) Contrast-enhanced MRI demonstrated a second ring-enhancing.

Figure Imaging, histology/immunohistochemistry, and schematic course of treatment with corresponding clinical and radiologic disease activity Imaging,

Figure 1 Representative spinal cord MRIs from patients with neuromyelitis optica Longitudinally extensive transverse myelitis of the cervical (A) and cervicothoracic.

Figure Forty-two months of follow-up of clinical symptoms in parallel with therapeutic interventions and antibody titers/B-cell count Forty-two months.

Figure 1 Full-length MOG cell-based assay using a serum dilution of 1:160 as a cutoff for positivity (red line in both plots)(A) Myelin olidgodendrocyte.

Figure 3 Effect of IVIg on endogenous relative concentration (in mAb equivalents) of JCV AbSix patients shown in this figure have had John Cunningham virus.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Figure Clinical course and overview of the treatment protocols♦ = neuroradiologic evidence of new disease activity; ★ = CD19+ reconstitution. Clinical.

Figure Spinal cord imaging (A, B) Sagittal and axial T2-weighted cervical spine MRI demonstrating hyperintensities in the central gray matter of patient.

Figure 2 Kaplan-Meier survival curves for the fingolimod cohort In each graph, bottom tertile: solid line; middle tertile: long dashed line; top tertile:

Figure 1 Follow-up periods of 33 anti–3-hydroxy-3-methylglutaryl coenzyme A reductase autoantibody (HMGCR Ab+) myopathy patients in relation to cancer.

Figure Clinical course and CSF/serum NMDA receptor (NMDAR) antibody (ab) titers of mother and infant Titers were measured with immunohistochemistry of.

Figure 1 Cell gating and binding curve from FACS experiments and M23 and M1 antibody titers during relapses and remission Cell gating for fluorescence-activated.

Figure 1 MRIs (case 1)‏ MRIs (case 1) An enlarging T2 lesion in the cerebral white matter near the angular gyrus and a new lesion in the left middle cerebellar.

Figure Rapid progression of lesions after natalizumab treatment(A) MRI from February Rapid progression of lesions after natalizumab treatment(A)

Figure 4 Patient 3 MRI evolution over time

Figure 2 Clinical data and variation of sNfL levels of patients 4–6 with ATZ-treated MS Clinical data and variation of sNfL levels of patients 4–6 with.

Figure 1 EDSS score (A), T2LV (B) and T1LV (C) courses in patients who experienced WNS after FTY withdrawal EDSS score (A), T2LV (B) and T1LV (C) courses.

Presentation transcript:

Figure 1 Relapse and rituximab historyThe figure shows rituximab (RTX) treatment history as well as relapse history for 100 days prior to the first RTX dose until the last follow-up. Relapse and rituximab historyThe figure shows rituximab (RTX) treatment history as well as relapse history for 100 days prior to the first RTX dose until the last follow-up. The shaded area shows the time period of interest—10 days after the initial RTX infusion (vertical lines). Note that the time scale for the shaded area is different from the rest of the chart in order to resolve the temporal relation between RTX infusion and relapse. Patient 1 is a 19-year-old Moroccan-born woman who experienced 2 relapses within 2 months of RTX treatment. Her last pre-RTX relapse was longitudinally extensive transverse myelitis (LETM), which was treated with IV methylprednisolone and 6 courses of plasmapheresis (PLEX). Due to failure to improve, she was given an infusion of RTX 10 days after PLEX, while on prednisone taper. She developed symptoms of worsening myelopathy and new-onset encephalopathy within 2 days of RTX. Brain MRI before and after RTX is shown in figure e-1, D and E. The patient was lost to follow-up after her discharge from the hospital 2 months later. Patient 2 is a 32-year-old African American woman who experienced LETM while on mycophenolate mofetil (MMF). Immunosuppression was then stopped. She received her first RTX treatment 3 months later and experienced another episode of LETM within 4 days of the infusion (figure e-1, A–C). She was then continued on MMF from 2009 to 2013 and had 2 relapses, the second of which was bilateral optic neuritis (ON) treated with IV methylprednisolone, PLEX, a single dose of IV cyclophosphamide, and a short course of filgrastin due to severe neutropenia. She received a dose of RTX—her second ever—1 month after cyclophosphamide and developed myelitis within 5 days of infusion, which was treated with IV methylprednisolone. She has subsequently received 3 doses of RTX without adverse reaction. Patient 3 is 39-year-old Caucasian woman who is anti–myelin oligodendrocyte glycoprotein antibody seropositive (1:5,120, Prof. Markus Reindl's laboratory, Innsbruck Medical University, Austria) and who experienced 3 relapses within 3 months of RTX. The last relapse was left ON for which she received IV methylprednisolone, 2 courses of PLEX, one dose of mitoxantrone, and then one dose of RTX. Despite “pretreatment” with mitoxantrone, the patient experienced recurrence of severe left ON with new area of enhancement of optic nerve on MRI within 3 days of infusion (figure e-1, F–H). She has subsequently received 5 courses of RTX and had only one mild episode of ON 2 weeks after the third RTX dose. Patient 4 is a 52-year-old Hispanic woman who experienced LETM while on azathioprine. She received IV methylprednisolone and was on prednisone at the time of her first RTX infusion, which was followed by recurrence of LETM 7 days later. She was subsequently maintained on MMF but had 2 relapses. Patient 5 is a 60-year-old Haitian-American woman who continued to have relapses despite treatment with mitoxantrone and azathioprine. Immunosuppression was stopped 5 months prior to RTX. Three months prior to RTX, she experienced bilateral ON and received IV methylprednisolone and PLEX. The first infusion of RTX was followed by recurrence of ON within 3 days. She subsequently received 2 more courses of RTX, and the last course was followed by recurrence of ON 2 weeks later. The patient died of sepsis 2 years after her last RTX dose. Patient 6 is a 58-year-old Afro-Caribbean woman with long-standing neuromyelitis optica who experienced 2 relapses of myelitis within 6 months while on azathioprine and discontinued immunosuppression 2.5 months before RTX. She had severe cervical myelitis within 1 week of her first RTX infusion. She was continued on RTX and remained remarkably relapse-free for 7 years, when she experienced a mild myelitis attack 2 weeks after regularly scheduled RTX. EDSS = Expanded Disability Status Scale. Jai S. Perumal et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e61 © 2015 American Academy of Neurology